2024-2025 COVID-19 Vaccines Provided Moderate Protection Against JN.1 Variants

Why It Matters

The findings confirm that current vaccines still reduce severe outcomes despite modest efficacy, guiding public‑health recommendations and future vaccine composition decisions.

Key Takeaways

• Overall VE 40% against JN.1 hospitalizations.
• Protection rises to ~52% after 90 days.
• Older adults (65+) see 45% effectiveness.
• Vaccinated proportion low among cases (11%).
• Study limited by sequencing gaps and prior immunity.

Pulse Analysis

The JN.1 sublineage emerged as the dominant SARS‑CoV‑2 strain in the United States during the 2024‑2025 winter, succeeding the XBB family and prompting the FDA to authorize updated vaccine formulations. Moderna and Pfizer leveraged the KP.2 spike protein, while Novavax introduced a JN.1‑specific antigen, reflecting a strategic shift toward lineage‑focused immunogens. This evolution illustrates the virus’s capacity for rapid antigenic drift, compelling manufacturers to anticipate future mutations and streamline regulatory pathways for timely updates.

In the IVY Network’s prospective case‑control study, immunocompetent adults who received a 2024‑2025 vaccine experienced a 40% reduction in COVID‑19‑related hospitalizations, with effectiveness climbing to 52% between 90 and 179 days post‑vaccination. Older adults (≥65) fared slightly better, achieving 45% overall protection. The median interval since vaccination was shorter among cases, suggesting waning immunity may influence outcomes. Although the study did not adjust for prior infection or earlier vaccine doses, the data provide a realistic snapshot of real‑world performance against a moderately immune‑evading variant.

For policymakers and health systems, the moderate yet durable protection underscores the importance of maintaining booster campaigns, especially for high‑risk populations. Continuous genomic surveillance and rapid vaccine redesign remain critical to counteract emerging lineages. As the pandemic transitions into an endemic phase, integrating variant‑specific effectiveness data into public‑health messaging can sustain vaccine confidence and optimize resource allocation for future immunization strategies.